Peptide Pharmacology

Menu

CJC (No DAC) / Ipamorelin Blend

  • Home
  • CJC/Ipamorelin Blend

Contents

What are CJC-1295 and Ipaamorelin?

CJC-1295 is a synthetic peptide developed to stimulate the release of growth hormone (GH) from the pituitary gland. It is an analog of growth hormone–releasing hormone (GHRH) but modified to have a much longer duration of action. Because growth hormone plays a central role in metabolism, muscle maintenance, fat breakdown, and recovery, CJC-1295 has attracted interest in clinical research.

Ipamorelin is a selective growth hormone secretagogue that works by mimicking a hormone named ghrelin. Ghrelin acts at the anterior pituitary to stimulate GH release without significantly affecting other pituitary hormones. It has gained promise in the research setting for its targeted action and relatively favorable side effect profile.

How Does CJC/Ipamorelin Blend Work?

CJC-1295 and Ipamorelin independently increase growth hormone release, however they act through distinct receptor pathways — GHRH and ghrelin receptors, respectively — and when combined, produce a synergistic amplification of GH output that exceeds what either peptide achieves alone.

What is CJC (No DAC) / Ipamorelin Blend Used for?

CJC/Ipamorelin Blend has been widely studied in preclinical research. Areas of interest include:

  • Age-related GH decline.
  • Body composition support
  • Muscle recovery and repair
  • Fat metabolism
  • Improving sleep quality

Side Effects of CJC (No DAC) / Ipamorelin Blend

Reported side effects are generally mild and may include injection site reactions, headache, or flushing. Because CJC-1295 stimulates endogenous GH release rather than replacing GH directly, it may carry a lower risk of abnormal hormone levels, though long-term safety data is still limited.

 

CJC/Ipamorelin Blend Research Dosing Protocol

CJC-1295 comes in two formulations: DAC and no DAC. The no DAC formulation is recommended when combined with ipamorelin, because the two have a similar dosing schedule in a 1:1 ratio. Hence, provided below is the recommended CJC-1295 (No DAC)/Ipamorelin blend dosing schedule.

  • 1Week 1: 0.2 mg daily total (0.1 mg of each component daily)
  • 2Week 2: 0.4 mg daily total (0.2 mg of each component daily)
  • 3Week 3: 0.6 mg daily total (0.3 mg of each component daily)
  • 4Weeks 4 and beyond: 0.8 mg daily total (0.4 mg of each component daily)
Click here to learn how to prepare peptides for research


CJC/Ipamorelin Blend Source (for Research)

GenPeptide.com

References

Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139:552-61. doi: 10.1530/eje.0.1390552.​

View Source

Smith RG. Development of growth hormone secretagogues. Endocr Rev. 2005 May;26:346-60. doi: 10.1210/er.2004-0019.

View Source

Fuh VL, et al. Growth hormone secretagogues: mechanism of action and use in aging. Growth Horm IGF Res. 1998 Feb;8:13-20. doi: 10.1016/s1096-6374(98)80317-1.

View Source

Giustina A, et al. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998 Dec;19(6):717-97. doi: 10.1210/edrv.19.6.0353.

View Source

Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91:799-805. doi: 10.1210/jc.2005-1536.

View Source